Article
A pilot study testing the genetic polymorphism of N-acetyltransferase 2 as a risk factor in lung cancer.
Neoplasma - 1 Jan 2005
Habalová V, Salagovic J, Kalina I, Stubna J
Abstract excerpt
NAT2 as phase II enzyme is involved in the detoxification/activation of various drugs, environmental substances and carcinogenic compounds. A genotyping approach has been used to investigate NAT2 genotype with putative relevance in lung cancer in population of 110 Slovak-Caucasians patients and 167 non-malignant individuals from the same region. Slow acetylation was not observed to be a significant risk factor of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
